Indeed, MS drugs may exacerbate antibody-mediated diseases such as AQP4-IgG+ NMOSD or be ineffective in MOGAD4, and thus, there is a caution in seronegative NMO.5 Thus, the diagnosis can be challenging but has important treatment implications. This evidence concerns the gene AQP4 and neuromyelitis optica.